H.R. 679 · 119th Congress · Health

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

In committee121 words Introduced Jan 23, 2025 · Latest action Jan 23, 2025

How far it has goneStage 2 of 6
  1. IntroducedJan 23, 2025 Done
  2. CommitteeReferred to Energy and Commerce Current stage
  3. House floorNot yet Not reached yet
  4. Senate floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)

The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions.

In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers.

The bill nullifies the January 2023 changes and prohibits any similar changes in the future.

Congressional Research Service · summary of “Introduced in House” version · Jan 23, 2025

Who lobbies on it

2 organizations · 10 filings · Q1 2025–Q3 2026

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Susan B Anthony List 6 of 7 quarters
    “Shield laws Chemical abortion drugs H.R.1 - Working Families Tax Cuts Act; H.R.6945, S.4242 - Supporting Pregnant and Parenting Women and Families Act; H.R. 7, S. 186 No Taxpayer Funding for Abortion and Abortion Insurance Full Disclosure Act of 2025; S. 2955; HR 6466 - Forced Abortion Prevention and Accountability…”

    Q2 2026 filing · $1.1M lobbying spend in 2026 to date, all issues

  2. Students for Life Action 4 of 7 quarters
    “Ending Chemical Abortion Act H.R. 692 Born-Alive Abortion Survivors Protection Act H.R. 21 Born-Alive Abortion Survivors Protection Act S. 6 Life at Conception Act H.R. 722 Protecting Life and Taxpayers Act H.R. 272 Defund Planned Parenthood Act H.R. 271 Womens Protection in Telehealth Act H.R 1349 Ultrasounds Saves…”

    Q4 2025 filing · Under $5,000 lobbying spend in 2025, all issues

Organizations that named H.R. 679 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.

Actions

2 actions · newest first
  1. Jan 23, 2025Referred to the House Committee on Energy and Commerce.
  2. Jan 23, 2025Introduced in House